Get the Stockscreener App
10.28
0.10%
0.010
Omeros Corp stock is traded at $10.28, with a volume of 1.09M.
It is up +0.10% in the last 24 hours and up +0.78% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$10.27
Open:
$10.18
24h Volume:
1.09M
Relative Volume:
0.63
Market Cap:
$744.02M
Revenue:
-
Net Income/Loss:
$84.01M
P/E Ratio:
12.01
EPS:
0.856
Net Cash Flow:
$-101.16M
1W Performance:
+10.78%
1M Performance:
+0.78%
6M Performance:
-17.69%
1Y Performance:
+197.11%
1-Day Range:
$9.94
$10.35
1-Week Range:
$9.25
$10.69
52-Week Range:
$3.34
$17.65
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
10.28 | 744.02M | 0 | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? - AOL.com
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? - The Motley Fool
Omeros shares drop 19% after EMA rejects narsop... - Pluang
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments - Seeking Alpha
Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now? - Insider Monkey
Omeros Corporation Files SEC Form 8-K for Other Events – Nasdaq: OMER, July 2026 - Minichart
Omeros to repurchase $16M of 9.50% notes, may buy up to $14.5M more - TradingView
Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt - Stock Titan
5 Best Get Rich Quick Stocks to Buy Right Now - Insider Monkey
Omeros Corporation Reports First Quarter 2026 Financial Results - The National Law Review
Omeros stock drops 19% after EU rejects key dru... - Pluang
OMEROS CORP (OMER) Stock Chart - ChartMill
Omeros stock crashes on regulatory setback: Buy the dip? - MSN
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Sahm
Crude Oil Falls 4%; US Consumer Sentiment Rises In June - Sahm
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? - AOL.com
Omeros Corp (OMER) Institutional Confidence - TradingKey
Omeros Corp (OMER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Omeros Corp (OMER) Valuation: PE, PB & Fair Value Analysis - TradingKey
Omeros (OMER) Faces Regulatory Setback for Narsoplimab Approval - GuruFocus
Omeros stock crashes on regulatory setback: buy the dip? - Invezz
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
OMER Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Why is Omeros stock tumbling today? - Investing.com
Omeros' Stem Cell Transplant Treatment Hits Regulatory DivideOmeros (NASDAQ:OMER) - Benzinga
European regulator issues negative opinion on Omeros’ TA-TMA drug - Investing.com
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA - BioSpace
Omeros (OMER) Shares Drop 25% Following EMA Panel's Negative Opi - GuruFocus
Omeros stock tumbles after EMA panel rejects narsoplimab application - Investing.com
Why Is OMER Stock Falling Today? - Yahoo Finance
Omeros EU review turns negative on rare transplant complication drug - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
Omeros stock tumbles after EU panel rejects Yartemlea - Investing.com
Omeros stock tumbles after EU panel rejects Yartemlea By Investing.com - Investing.com UK
OMER Forecast — Price Target — Prediction for 2027 - TradingView
[8-K] OMEROS CORP Reports Material Event - Stock Titan
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? - AOL.com
Form 4 Omeros Corporation For: 22 June By Investing.com - Investing.com Australia
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omeros Corp Stock (OMER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cable Thomas J. | Director |
May 22 '26 |
Sale |
11.61 |
7,500 |
87,039 |
35,067 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):